您的位置：
首页
>
农业专利
>
详情页
NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF
专利权人:
TLL Pharmaceutical; LLC
发明人:
Congxin Liang
申请号：
US16333994
公开号：
US20190256523A1
申请日:
2017.09.30
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The new 1H-furo[3,2-b]imidazo[4,5-d]pyridine derivatives are selective Jak1 kinase inhibitors useful in treating disorders related to Jak1 activities such as autoimmune diseases or disorders, inflammatory diseases or disorders, and cancer or neoplastic diseases or disorders.
来源网站：
中国工程科技知识中心
来源网址：
http://www.ckcest.cn/home/
相关专利
IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMERS DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA
IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMERS DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA
A SIK INHIBITOR FOR USE IN A METHOD OF TREATING AN INFLAMMATORY AND/OR IMMUNE DISORDER
IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMERS DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA
Tricyclic FUSED thiophene Compounds, inhibitors of Janus Kinase (JAK)； Pharmaceutical composition that comprises； a method for inhibiting the activity of JAK1； a method for treating an autoimmune disease, cancer, a myeloproliferative disorder and Disease inflamat Oria, among other diseases.
